Abstract
Fabry disease is a multisystem X-linked disorder resulting from α-galactosidase A (α-GalA) gene mutations leading to the accumulation of globotriaosylceramide mainly in endothelium compromising heart, kidney, and brain. In Fabry patients, progressive renal failure is frequently treated with angiotensin I-converting enzyme (ACE) inhibitors. We were interested in the possible interactions between ACE inhibitors therapy and the only causative therapy for Fabry disease, the enzyme replacement therapy (ERT) using recombinant human α-GalA (rhα-GalA). Our results suggest that ACE activity was significantly inhibited in plasma of Fabry patients and the blood pressure level decreased just after ERT (at the end of the rhα-GalA infusion). Interestingly, 2 weeks later, ACE activity was significantly upregulated and the plasma levels of angiotensin II increased in the patients treated with rhα-GalA following the elevations of ACE activity. The same inhibitory effect on ACE activity was also observed in rats after rhα-GalA infusion. Furthermore, ACE activity in CHO cells transfected with the human ACE was inhibited dose and time-dependently by rhα-GalA. In vitro, the incubation of plasma from healthy volunteers with rhα-GalA significantly reduced ACE activity. Finally, rhα-GalA also inhibited ACE activity and released galactose residues from purified rabbit lung ACE dose-dependently. In summary, our results suggest that rhα-GalA interacts with ACE and inhibits its activity, possibly by removing the galactose residues from the enzyme. This modulation might have profound impact on the clinical outcome of Fabry patients treated with rhα-GalA.
Similar content being viewed by others
References
Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Lastes L (1967) Enzymatic defect in Fabry’s disease Ceramidetrihexosidase deficiency. N Engl J Med 276(21):1163–1167
Bloom D, Speijer D, Linthosrt GE, Donker-Koopman WG, Strijland A, Aerts JMFG (2003) Recombinant enzyme therapy for Fabry disease: absence of editing of human α-galactosidase A mRNA. Am J Hum Genet 72:23–31
Clarke TR (2007) Narrative review: Fabry disease. Ann Intern Med 146:425–433
Brady RO, Schiffmann R (2000) Clinical features of and recent advances in therapy for Fabry disease. Jama 284:2771–2775
Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774
Matsuzawa F, Aikawa SI, Doi H, Okumiya T, Sakuraba H (2005) Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes. Hum Genet 117:317–338
MacDermot KD, Holmes A, Miners AH (2001) Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760
Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litvalk S, Nagle JW, Schiffmann R (2001) Identification of fifteen novel mutations and genotype–phenotype relationship in Fabry disease. Clin Genet 60(46):51
Desnick RS, Brady R, Barrenger J, Collins AJ, Germain DP, Goldman M, Grabowsiki G, Packman S, Wilcose WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346
Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA III et al (2002) Natural history of Fabry renal disease: influence of alfa-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122–138
MacDermot KD, Holmes A, Miners AH (2001) Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 24(2):13–14
Vedder AC, Linthorst GE, van Breemen MJ, Groener JEM, Bemelman FJ, Strijland A, Mannens MMAM, Aerts JMFG, Hollak CEM (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, Van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. PNAS 105(8):2812–2817
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alfa-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749
MacDermot KD, Holmes A, Miners AH (2001) Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775
Vedder AC, Linthorst GE, Houge G, Groener JEM, Ormel EE, Bouma BJ, Aerts JMFG, Hirth A, Hollak CEM (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2(7):e598. doi:10.1371/journal.pone.0000598
Eng CM, Germain DP, DP BM, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K et al (2006) Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med 8(9):539–548
Griedling KK, Murphy TJ, Alexander RW (1993) Molecular biology of the renin-angiotensin system. Circulation 87:1816–1828
Cushman DW, Cheung HS (1971) Concentration of angiotensin converting enzyme in tissues of rat. BBA 250:261–265
Mendelsohn FAO, Allen AM, Chai SY, McKinley MJ, Oldfield BJ, Paxinos G (1990) The brain angiotensin system: insights from mapping its components. Trends Endocrinol Metab 1:189–197
Carluccio M, Soccio M, De Caterina R (2001) Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest 31:476–488
Araujo MC, Melo RL, Cesari MH, Juliano MA, Juliano L, Carmona AK (2000) Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39:8519–8525
Ronchi FA, Andrade MC, Carmona AK, Krieger JE, Casarini DE (2005) N-domain angiotensin-converting enzyme isoform expression in tissues of Wistar and spontaneously hypertensive rats. J Hypertens 23(10):1793–1794
Sabatini RA, Bersanetti PA, Farias SL, Juliano L, Juliano MA, Casarini DE, Carmona AK, Paiva ACM, Pesquero JB (2007) Determination of angiotensin I-converting enzyme activity in cells in culture using fluorescence resonance energy transfer peptides. Anal Biochem 363:255–262
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 1:265–275
Hoffmann B (2009) Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis 4:21
Wright JT, Bakris G, Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG (2002) African American study of kidney disease and hypertension study group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 288:2421–2431
Remuzzi G, Ruggenenti P, Perico N (2002) Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136:604
Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG (2004) Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 12:929–937
Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G (2000) Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155–1165
Sarafidis PA, Khosla N, Bakris GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49:12–26
Warnock DG (2009) Optimizing treatment to reach therapeutic goals in Fabry disease. Clinical Therapeutics 31, Supplement A
Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617
Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T, Chiba Y, Takashiba M, Jigami Y, Fukushige T (2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51:180–188
Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18:1576–1583
Baudin B, Alves N, Pilon A, Beneteau-Burnat B, Giboudeau J (1997) Structural and biological roles of glycosylation in pulmonary angiotensin I-converting enzyme. Glycobiology 7:565–570
Ramchandran R, Kasturi S, Douglas JG, Sen I (1996) Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am J Physiol 271:H744–H751
Sadhukhan R, Santhamma KR, Reddy P, Peschon JJ, Black RA, Sen I (1999) Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alphaconverting enzyme-deficient mice. J Biol Chem 274:10511–10516
Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P (1988) Two putative active centers in human angiotensin I converting enzyme revealed by molecular cloning. Proc Natl Acad Sci 85:9386–9390
Ripka JE, Ryan JW, Valido FA, Chung AYK, Peterson CM, Urry RL (1993) N-glycosylation of forms of angiotensin converting enzyme from four mammalian species. Biochem Biophys Res Commun 196:503–508
Yu XC, Sturrock ED, Wu Zh, Biemann K, Ehlers MRW, Riordan JF (1997) Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form. J Biol Chem 272:3511–3519
Kost OA, Bovin NV, Chemodanova EE, Nasonov VV, Orth TA (2000) New feature of angiotensin-converting enzyme: carbohydrate-recognizing domain. J Mol Recognit 13:360–369
Gralnick HR, Kramer WS, McKeown LP, Garfinkel L, Pinot A, Williams SB, Krutzsch H (1996) Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the beta 1 integrin alpha 2 beta 1. Thromb Res 81(1):113–119
Conroy JM, Hartley JM, Soffer RL (1978) Canine pulmonary angiotensin-converting enzyme: Physicochemical, catalytic and immunological properties. Biochim Biophys Acta 524:403–412
Orth T, Voronov S, Binevski P, Saenger W, Kost OA (1998) Glycosylation of bovine pulmonary angiotensin-converting enzyme modulates its catalytic properties. FEBS Lett 431:255–258
Corvol P, Williams TA, Soubrier F (1995) Dipeptidyl dipeptidase: angiotensin-converting enzyme. Meth Enzymol 248:283–305
Ehlers MRW, Riordan JF (1989) Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 28:5318–5322
Sources of funding
This work was supported by Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP, 2008/06676-8), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Probral CAPES/DAAD, 239/06), Deutsche Akademische Austauschdienst (DAAD/PROBRAL) and Deutsche Forschungsgemeinschaft (BA 1374/16-1). Elice Carneiro Batista was supported by a doctoral fellowship from CAPES PROEX (Nr.33009015001).
Disclosures
María Verónica Muñoz Rojas works as medical manager, Genzyme do Brasil. Fabrazyme is manufactured by Genzyme for Fabry disease patient treatment.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Batista, E.C., Carvalho, L.R., Casarini, D.E. et al. ACE activity is modulated by the enzyme α-galactosidase A. J Mol Med 89, 65–74 (2011). https://doi.org/10.1007/s00109-010-0686-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-010-0686-2